VBS Vectus Biosystems Limited
—Mkt Cap: —P/E: —1d ago
Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops a pipeline of antifibrotic assets targeting cardiovascular, renal and liver fibrosis to address dise…
Industry Peers
Biotechnology$128.87BUSDP/E 29.6
$94.42BUSD
$81.99BUSDP/E 19.1
$53.47BUSDP/E 32.5
$53.22BUSDP/E 31.6
$44.02BUSDP/E 17.8
$42.56BUSDP/E 66.4
$40.57BUSD
$34.45BUSDP/E 30.4
$31.32BUSDP/E 39.3
$24.59BUSD
$23.32BUSDP/E 31.7
$23.26BUSDP/E 29.8
$22.96BUSDP/E 14.0
$22.66BUSD
$21.67BUSD
$15.57BUSDP/E 19.3
$14.91BUSDP/E 17.4
$13.92BUSDP/E 14.7
$13.79BUSDP/E 33.4
Key Statistics
Company
Market Cap—
Enterprise Value2.42M USD
Revenue (TTM)1.91M USD
Gross Profit1.91M USD
Net Income (TTM)1.08M USD
Revenue/Share0.05 AUD
Last Price—
Fiscal Year EndJun 2026
MR QuarterJun 2026
Employees—
CountryAU
SectorHealthcare
IndustryBiotechnology
ISINAU000000VBS9
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA2.50
EV/Revenue1.27
P/S2.36
P/B2.76
EPS (TTM)0.03
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin100.00%
Oper. Margin76.36%
EBITDA Margin50.71%
Profit Margin56.33%
ROE139.32%
ROA37.42%
Growth
Revenue Growth3169.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-396.26K USD
CapEx (TTM)46.92K USD
FCF Margin51.97%
FCF Yield—
Net Debt-2.05M USD
Net Debt/EBITDA-2.12
Balance Sheet
Debt/Equity0.02
Current Ratio3.79
Quick Ratio3.73
Book Value/Sh0.04 AUD
Cash/Share0.06 AUD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 AUD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.62.18M
Float28.94M
Insiders50.90%
Institutions6.45%
Technical
SMA 500.1422 AUD
SMA 2000.1383 AUD
Beta0.51
S&P 52W Chg16.44%
Avg Vol (30d)—
Avg Vol (10d)37.54K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—